US45826J1051 - NTLA - A2AG6H (XNMS)
INTELLIA THERAPEUTICSCS INC Aktie
23,02 USD
Aktuelle Kurse von INTELLIA THERAPEUTICSCS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
NTLA
|
USD
|
20.09.2024 00:02
|
23,02 USD
| 22,52 USD | 2,22 % |
London |
0JBU.L
|
USD
|
19.09.2024 17:13
|
23,64 USD
| 22,52 USD | 4,97 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
2,22 % | 10,18 % | 1,72 % | -7,18 % | -17,16 % | -33,06 % | 54,81 % |
Firmenprofil zu INTELLIA THERAPEUTICSCS INC Aktie
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Investierte Fonds
Folgende Fonds haben in INTELLIA THERAPEUTICSCS INC investiert:
Fonds | Vol. in Mio 392,59 | Anteil (%) 0,92 % |
Unternehmensdaten zur INTELLIA THERAPEUTICSCS INC Aktie
Name INTELLIA THERAPEUTICSCS INC
Firma Intellia Therapeutics, Inc.
Symbol NTLA
Website https://www.intelliatx.com
Heimatbörse
NASDAQ/NMS (GLOBAL MARKET)
WKN A2AG6H
ISIN US45826J1051
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. John M. Leonard M.D.
Marktkapitalisierung 2 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,5 T
Adresse 40 Erie Street, 02139 Cambridge
IPO Datum 2016-05-06
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | 38I.F |
London | 0JBU.L |
NASDAQ | NTLA |
Weitere Aktien
Investoren die INTELLIA THERAPEUTICSCS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024